A study published recently in the Journal of the American Medical Association has found that administering zoledronic acid every 12 weeks instead of the current standard of every four weeks over two years, does not increase the risk of skeletal-related events (SREs) in patients with bone complications due to breast cancer, prostate cancer or myeloma.…
These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.
Results from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was…
Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…
A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…
The Myeloma UK Clinical Trial Network (CTN) has achieved another significant milestone with data from the MUK six trial published in the latest issue of Lancet Haematology. MUK six, a Phase I/II multicentre open label trial aimed to determine the safety and both the optimum and maximum dose of panobinostat when used in combination with once-weekly Velcade,…
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
